Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma - A Southeastern Cancer Study Group trial

Edwin B. Cox, Charles L. Vogel, John T. Carpenter, Marilyn Raney

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2 by IV infusion for five consecutive days every three weeks. Toxicity was primarily gastrointestinal and hematologic and was frequently severe. This study demonstrated no therapeutic activity for teniposide when given in this dose and schedule to patients with heavily pretreated metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)37-40
Number of pages4
JournalInvestigational New Drugs
Volume6
Issue number1
DOIs
StatePublished - Apr 1 1988

Keywords

  • breast cancer
  • breast carcinoma
  • teniposide

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma - A Southeastern Cancer Study Group trial'. Together they form a unique fingerprint.

  • Cite this